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Abstract
Significance: 8-Hydroxy-2-deoxyguanosine (8-OHdG) is generated after the repair of ROS-mediated DNA
damages and, thus, is one of the most widely recognized biomarkers of oxidative damage of DNA because
guanosine is the most oxidized among the DNA nucleobases. In several pathological conditions, high urinary
levels of oxidized DNA-derived metabolites have been reported (e.g., cancer, atherosclerosis, hypertension, and
diabetes). Recent Advances: Even if published studies have shown that DNA damage is significantly associated
with the development of atherosclerosis, the exact role of this damage in the onset and progression of this
pathology is not fully understood, and the association of oxidative damage to DNA with cardiovascular disease
(CVD) still needs to be more extensively investigated. We performed a meta-analysis of the literature to inves-
tigate the association among 8-OHdG levels and CVD. Critical Issues: Fourteen studies (810 CVD patients and
1106 controls) were included in the analysis. We found that CVD patients showed higher 8-OHdG levels than
controls (SMD: 1.04, 95%CI: 0.61, 1.47, p < 0.001, I2 = 94%, p< 0.001). The difference was confirmed both in
studies in which 8-OHdG levels were assessed in urine (MD: 4.43, 95%CI: 1.71, 7.15, p= 0.001) and in blood
samples (MD: 1.42, 95%CI: 0.64, 2.21, p = 0.0004). Meta-regression models showed that age, hypertension, and
male gender significantly impacted on the difference in 8-OHdG levels among CVD patients and controls.Future
Directions: 8-OHdG levels are higher in patients with CVD than in controls. However, larger prospective studies
are needed to test 8-OHdG as a predictor of CVD. Antioxid. Redox Signal. 24, 548–555.
Introduction
The occurrence of cardiovascular disease (CVD) ismultifactorial and major risk factors are type 2 diabetes,
hypertension, smoking, overweight, dyslipidemia (45). In this
context, the generation of reactive oxygen species (ROS),
which is important in both normal physiology and in the
pathogenesis of many diseases, seems to play a relevant role
also in CVD development (5). In physiological conditions,
ROS are scavenged by the antioxidant system, but when their
concentration is too high, an oxidative damage to proteins,
lipids, and DNA occurs (39). DNA damages are usually re-
paired by a specific system and the oxidized products are ex-
creted in urine (38) without further metabolism. Increased
urinary levels of the oxidized metabolites were associated
with an increased risk of several pathological conditions (8).
One of the most widely studied metabolite is 8-hydroxy-2-
deoxyguanosine (8-OHdG), which is considered as a bio-
marker of oxidative damage ofDNA (4, 18) because guanosine
is the most oxidized among the DNA nucleobases. High levels
of 8-OHdGhavebeen found in fragments of aorta frompatients
with severe atherosclerotic lesions. In addition, 8-OHdG levels
1Centro Cardiologico Monzino, IRCCS, Milan, Italy.
2Dipartimento di Scienze Cliniche e di Comunita`, Universita` degli Studi di Milano, Milan, Italy.
3Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University, Naples, Italy.
ª Alessandro Di Minno et al. 2016; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the
Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncom-
mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
ANTIOXIDANTS & REDOX SIGNALING
Volume 24, Number 10, 2016
Mary Ann Liebert, Inc.
DOI: 10.1089/ars.2015.6508
548
have been correlated with the number of vessels involved by
the atherosclerotic process (29, 46). The relationship between
8-OHdG and atherogenic risk factors has been extensively
studied (10). For example, 8-OHdG concentrations were
higher in patients with diabetes (36) and hypertension (33).
Even if published studies have shown that DNA damage is
significantly associated with the development of atheroscle-
rosis (1, 34), the exact role of this damage in the onset and
progression of this pathology is not fully understood and the
association of oxidative damage to DNAwith CVD still needs
to be more extensively investigated. For this reason, we per-
formed a systematic review and meta-analysis of literature to
investigate the association among 8-OHdG levels and CVD.
Methods
A protocol for this review was prospectively developed,
detailing the specific objectives, the criteria for study selec-
tion, the approach to assess study quality, the outcomes, and
the statistical methods.
Search strategy
To identify all available studies, a detailed search pertaining
to 8-OHdG levels and CVD was conducted according to
PRISMA (Preferred Reporting Items for Systematic reviews
and Meta-Analyses) guidelines (27). A systematic search was
performed in the electronic databases (PubMed, Web of Sci-
ence, Scopus, EMBASE), using the following search terms in
all possible combinations: 8-hydroxy-2-deoxyguanosine, 8-
hydroxy-2-deoxy guanosine, 8-OHdG OR 8OHdG, 8-OH-dG,
8-OHG,8-oxo-G,8-oxo-dG, 8-hydroxydeoxyguanosine, 8-oxo-
guanine, 8-hydroxy-2-deoxyguanosine OR 8-hydroxyguanine,
8-hydroxyguanosine, 8-oxo-2-deoxyguanosine, 8-oxo-7,8-
dihydro-2-deoxyguanosine, coronary artery disease, ath-
erosclerosis, ischaemic heart disease, stroke, myocardial
infarction, cardiovascular disease, coronary artery disease.
The last search was performed on November 11, 2015. The
search strategy was developed without any language or publi-
cation year restriction.
In addition, the reference lists of all retrieved articles were
manually reviewed. In case of missing data, study authors
were contacted by e-mail to try to retrieve original data. Two
independent authors (A.D.M. and M.N.D.D.M) analyzed
each article and performed the data extraction independently.
In case of disagreement, a third investigator was consulted
(L.T.). Discrepancies were resolved by consensus. Selection
results showed a high inter-reader agreement (j = 0.96) and
have been reported according to PRISMA flowchart (Sup-
plementary Fig. S1; Supplementary Data are available online
at www.liebertpub.com/ars).
Data extraction and quality assessment
According to the prespecified protocol, all studies evalu-
ating 8-OHdG levels in CVD patients were included. Case
reports, reviews, and animal studies were excluded. To be
included in the analysis, a study had to provide levels of 8-
OHdG in CVD patients (coronary artery disease [CAD],
stroke, peripheral artery disease, and carotid atherosclerosis)
and controls. To allow for a pooled analysis of data, studies
dosing 8-OHdG levels on samples different from urine or
blood (i.e., histological samples), lacking a control group,
including a study population with a clinical condition other
than CAD, stroke, peripheral artery disease, and carotid
atherosclerosis, were excluded from the analysis.
In each study, data regarding sample size, major clinical
and demographic variables of patients and controls, and type
of 8-OHdG measurement (enzyme-linked immunosorbent
assay [ELISA] or mass spectrometry [MS]) were extracted.
Formal quality score adjudication was not used since previ-
ous investigations failed to demonstrate its usefulness (17).
Statistical analyses and risk of bias assessment
Statistical analysis was carried out using the Review
Manager software (Version 5.2; The Cochrane Collabora-
tion, Copenhagen, Denmark). Because of the heterogeneity
in the methods used for measuring 8-OHdG in included
studies, differences among cases and controls were expressed
as standard mean difference (SMD) with pertinent 95%
confidence interval (95% CI). According to widely accepted
guidelines, SMD is considered small if ranging from 0.2 to
0.5, medium if 0.5–0.8, and large if >0.8. (9)When separately
assessing studies in which 8-OHdG levels were evaluated in
urine and blood, differences among cases and controls were
expressed as mean difference (MD) with 95%CI. The overall
effect was tested using Z scores and significance was set at
p < 0.05. Statistical heterogeneity between studies was as-
sessed with chi-square Cochran’s Q test and with I2 statistic,
which measures the inconsistency across study results and
describes the proportion of total variation in study estimates
that is due to heterogeneity rather than sampling error. In
detail, I2 values of 0% indicate no heterogeneity, 25% low,
25–50% moderate, and 50% high heterogeneity (12). Pub-
lication bias was assessed by the Egger’s test and represented
graphically by funnel plots of the standard difference in
means versus the standard error. Visual inspection of funnel
plot asymmetry was performed to address for possible small-
study effect, and Egger’s test was used to assess publication
bias, over and above any subjective evaluation. A value of
p < 0.10 was considered statistically significant (41). In case
of a significant publication bias, Duval and Tweedie’s trim
and fill method was used to allow for the estimation of an
adjusted effect size (6). To be as conservative as possible, the
random-effect method was used for all analyses to take into
account the variability among included studies.
Sensitivity analyses
In the frame of a sensitivity analysis, results have been
stratified according to the type of vascular disease (CAD,
stroke, peripheral artery disease, and carotid atherosclerosis)
and study design (prospective or retrospective). Given the
potential influence of type of 8-OHdG measurement on the
overall effect size, we planned to perform separate analyses
for studies using ELISA and those using MS. Moreover, we
separately analyzed studies dosing 8-OHdG on urine and
studies dosing 8-OHdG on blood samples.
Metaregression analyses
We hypothesized that differences among included studies
may be affected by demographic variables (mean age, male
gender) and coexistence of traditional cardiovascular risk fac-
tors (hypertension, smoking habit, diabetes mellitus, obesity,
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hyperlipidemia). To assess the possible effect of such variables
in explaining different results observed across studies, we
planned to perform metaregression analyses after implement-
ing a regression model with 8-OHdG levels as dependent var-
iables (y) and the abovementioned covariates as independent
variables (x).This analysiswas performedwithComprehensive
Meta-analysis (Version 2; Biostat, Englewood, NJ).
Results
After excluding duplicate results, the search retrieved 877
articles. Of these studies, 847 were excluded because they
were off the topic after scanning the title and/or the abstract
and because theywere reviews/comments/case reports or they
lacked data of interest. A total of 16 studies were excluded
after full-length article evaluation (Supplementary Table S1).
Thus, 14 studies (2, 3, 5, 13, 15, 16, 21, 24, 25, 28, 30, 35,
37, 46) on 810 CVD patients and 1106 controls were included
in the final analysis (Supplementary Fig. S1). In detail, three
studies on stroke (245 cases and 566 controls) (5, 24, 37),
seven on CAD (351 cases and 404 controls) (2, 3, 13, 21, 28,
30, 46), two on patients with carotid atherosclerosis under-
going carotid endarterectomy (134 cases and 66 controls)
(16, 35), and two on peripheral artery disease (80 cases and
70 controls) (15, 25) were included.
Study characteristics
Major characteristics of included studies are shown in
Table 1. A total of five studies (3, 15, 16, 24, 37) were case–
control studies and nine (2, 5, 13, 21, 25, 28, 30, 35, 46) had a
prospective design. In 11 studies, an ELISA was used to
perform 8-OHdG level assessment (2, 3, 5, 13, 15, 21, 25, 28,
30, 37, 46), and in 3 studies, liquid or gas chromatography
MS (16, 24, 35). As to the type of sample, in eight studies
(464 CVD patients and 376 controls), 8-OHdG levels were
assessed in urinary samples (2, 15, 16, 21, 24, 28, 35, 37), and
in six studies (346 CVD patients and 730 controls), blood
samples were used (3, 5, 13, 25, 30, 46).
The number of patients varied from 16 to 131, the mean
age from 55 to 71 years, and the prevalence of male gender
from 51.7% to 100%. The presence of hypertension was re-
ported by 16.5%–72.0% of patients, smoking habit by 24%–
47%, diabetes mellitus by 12.4%–40.9%, and dyslipidemia
by 10%–53.4%. Mean body–mass index (BMI) varied from
23.1 kg/m2 to 27.0 kg/m2.
In the 14 studies, we found that 810 CVD patients showed
significantly higher 8-OHdG levels than the 1106 controls
(SMD: 1.04, 95% CI: 0.61–1.47, p < 0.00001, I2 = 94%,
p < 0.00001). As shown in Figure 1, the difference was con-
sistently confirmed both in studies in which 8-OHdG levels
were assessed in urine (MD: 4.43 ng/mg creatinine, 95% CI:
1.71–7.15, p = 0.001) and in studies using blood samples
(MD: 1.42 ng/ml, 95% CI: 0.64–2.21, p = 0.0004). Hetero-
geneity among studies was statistically significant in all cases
(I2 = 98%, p < 0.00001 and I2 = 94%, p < 0.00001, respec-
tively) and no reduction in the overall heterogeneity was
found after excluding one study at a time.
Sensitivity analysis
As shown in Table 2, similar results were obtained when
stratifying analysis according to the type of vascular disease
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(CAD, stroke, peripheral artery disease, and carotid athero-
sclerosis), different 8-OHdG measurement techniques, and
study design.
Metaregression analyses
Metaregression models showed that an increasing mean
age and an increasing prevalence of hypertension in the
study population were associated with a lower difference in
8-OHdG levels among CVD patients and controls (Fig. 2). In
contrast, a higher difference in 8-OHdG levels among CVD
patients and controls was found in the presence of a higher
prevalence of male gender (Fig. 2). All the other clinical and
demographic variables tested did not influence the associa-
tion between 8-OHdG and CVD (Supplementary Fig. S2).
Publication bias
Because it is recognized that publication bias can affect the
results of meta-analyses, we attempted to assess this potential
bias using funnel plot analysis. Funnel plots of effect size
versus standard error for studies evaluating levels of 8-OHdG
in CVD patients and controls were rather asymmetrical, and
the Egger test confirmed the presence of a significant publi-
cation bias (Egger = 0.001, Supplementary Fig. S3). How-
ever, the adjusted analysis by means of Duval and Tweedie’s
trim and fill method confirmed differences in 8-OHdG levels
among CVD patients and controls with an SMD of 1.25 (95%
CI: 0.72–1.78, Supplementary Fig. 3).
Discussion
This is the first meta-analysis, to our best knowledge,
showing that 8-OHdG levels are higher in patients with CVD
than in controls. Interestingly, these datawere confirmedwhen
separately evaluating studies, including CAD patients, and
those on patients with other types of atherosclerotic processes
(stroke, peripheral artery disease, and carotid atherosclerosis).
Further relevant information was derived from the metar-
egression analysis, showing that the association among
FIG. 1. 8-OHdG levels
in CVD patients and con-
trols. 8-OHdG, 8-hydroxy-2-
deoxyguanosine; CVD, car-
diovascular disease.
Table 2. Subgroup Analysis: Stratification of the Analysis According to Different Vascular Diseases
(Coronary Artery Disease, Stroke, Peripheral Artery Disease, and Carotid Atherosclerosis) (A), Different
Techniques (B), and Samples (C) Used for 8-OHdG Measurement
No. of
studies
No. of
patients Effect size
Test for subgroup
differences
(A) Different type of cardiovascular disease
Coronary artery disease 7 351 Cases SMD: 1.24; 95% CI: 0.47 to 2.01,
p < 0.002, I2: 95%, p < 0.00001
v2: 0.75, p= 0.39
404 Controls
Noncoronary artery diseasesa 7 459 Cases SMD: 0.83; 95% CI: 0.33 to 1.34,
p = 0.001, I2: 91%, p £ 0.0001702 Controls
(B) Different techniques for 8-OHdG measurement
ELISA 11 545 Cases SMD: 1.09; 95% CI: 0.60 to 1.58,
p < 0.0001, I2: 93%, p < 0.00001
v2: 0.16, p= 0.69
909 Controls
GC/LC-MS 3 265 Cases SMD: 0.86; 95% CI: -0.15 to 1.87,
p = 0.09, I2: 95%, p< 0.00001197 Controls
(C) Different study design
Case–control studies 5 325 Cases SMD: 1.00; 95% CI: -0.30 to 1.71,
p = 0.005, I2: 94%, p < 0.00001
v2: 0.02, p= 0.90
360 Controls
Prospective studies 9 485 Cases SMD: 1.06; 95% CI: 0.48 to 1.65,
p = 0.0004, I2: 94%, p < 0.00001746 Controls
aIncluding three studies on stroke, two on carotid atherosclerosis, and two on peripheral artery disease.
95% CI, 95% confidence interval; SMD, standard mean difference.
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8-OHdG levels and CVD is largely independent of diabetes,
hyperlipidemia, BMI, and smoking habit. In contrast, an in-
creasing age significantly impacted on the effect size, with
the association among 8-OHdG levels and CVD being
stronger in younger subjects. Thus, 8-OHdG might represent
a better marker of CVD in a young population. This might be
consequent to the reduction in DNA turnover associated with
aging (11). Similarly, an increasing prevalence of hyperten-
sion in the study population was associated with a lower
difference in 8-OHdG levels among CVD patients and con-
trols. This might be explained by some evidence suggesting
that 8-OHdG levels are significantly higher in hypertensive
subjects than normotensive controls (31). These data are in
line with results of the study by Mendes et al. (26), showing
that patients with cardiovascular risk factors have threefold
higher levels of urinary 8-OHdG than controls.
We also found that gender might impact on the effect size
of our meta-analysis. Indeed, the difference in 8-OHdG levels
among CVD patients and controls was lower in female
gender than in males. This finding is supported by some
previously published data (23) suggesting that 8-OHdG lev-
els are higher in females. In addition, the inclusion of post-
menopausal women, in which the antioxidant effect of
estrogens has been lost, can partially explain this finding (32,
42). A further potential explanation of gender differences in
8-OHdG urinary levels can be represented by the higher
muscle mass of male subjects, thus leading to higher creati-
nine levels (7, 43).
Several cardiovascular risk factors, such as hypercholes-
terolemia, diabetes, hypertension, and atherosclerosis, are
associated with an increased oxidative stress (20), which is
the consequence of an imbalance between the generation of
ROS and the activity of antioxidant defense system, due to
endogenous or exogenous environmental factors and can
induce oxidation of biological macromolecules such as pro-
teins, lipids, and DNA (39).
Because of the high instability of ROS, the degree of ox-
idative stress can be better evaluated by the assessment of
stable metabolites of oxidative reactions. 8-OHdG is a
product of oxidative DNA damage and is widely recognized
as a biomarker of the in vivo total systemic oxidative stress
(38, 40, 47).
Oxidative stress is implicated in the pathogenesis of sev-
eral diseases such as cancer, ischemia/reperfusion injury,
diabetes, neurodegenerative and immunoinflammatory dis-
eases, and atherosclerosis (44). In particular, the increase in
8-OHdG concentrations in CVD patients, secondary to ROS-
mediated DNA damage, could mirror severity of the ath-
erosclerotic process (22).
However, available studies on this issue are heteroge-
neous, providing contrasting results on the association among
8-OHdG levels and CVD. This meta-analysis, by pooling
together 14 studies enrolling 810 CVD patients and 1106
controls, has allowed to further address this issue. Moreover,
two studies by Ho et al. (14) and Kaya et al. (19), not included
in the present meta-analysis because they performed the
evaluation of DNA damage in DNA extracted from white
blood cell and expressed the ratio between 8-OHdG and
106 dG (Supplementary Table S1), widely confirmed our
results. When pooling together data from these two studies,
we found higher levels of 8-OHdG in the 154 CAD patients
than in the 97 controls (SMD: 1.79, 95% CI: 1.49–2.09,
p < 0.001, I2: 0%, p = 0.45). Thus, data obtained on this bio-
logical matrix confirm and strengthen findings reported on
urine and blood samples.
In another study (29), also not included, patients with heart
failure were divided in two groups on the basis of CAD
presence. This study showed no statistical difference between
patients with or without CAD. When patients were divided in
four subgroups on the basis of the New York Heart Asso-
ciation functional classification, the difference, in terms of
8-OHdG, between patients with a more severe CAD and
controls became statistically significant.
Moreover, confirming and extending the association be-
tween 8-OHdG levels and CAD, two studies showed a pro-
gressive reduction of 8-OHdG levels in CAD patients after
reperfusion (13, 28).
Our study has some potential limitations. First, studies
included in this meta-analysis have different inclusion and
exclusion criteria and most of patients included in the anal-
ysis had concomitant cardiovascular risk factors and different
types of CVDs. Since this meta-analysis is performed on
aggregate data and some missing information is present in
each study, the metaregression approach allowed for the
adjustment for some (but not all) potential confounders.
FIG. 2. Metaregression analysis. Clinical and demo-
graphic characteristics impacting the effect size.
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Thus, although results of metaregression analyses were able
to refine analyses by assessing the influence of most clinical
and demographic variables on the observed results, caution is
necessary in overall result interpretation. However, although
the absence of a multivariate analysis hampers the exclusion
of a confounding effect due to other covariates potentially
affecting the association among 8-OHdG levels and CVD,
one of the included studies (46) showed that after adjusting
for male gender, smoking, hypertension, hyperlipidemia, dia-
betes mellitus, and age, 8-OHdG levels were independently
associated with the presence of CAD. In detail, a 0.1 ng/ml
increase in 8-OHdG concentrationwas associatedwith an odds
ratio of 1.318 (95% CI: 1.032–1.682, p= 0.027) for the pres-
ence of CAD (46).
The presence of significant heterogeneity among the
studies needs to be discussed. An important source of het-
erogeneity could be due to the variability in laboratory
methods used to evaluate 8-OHdG. A validated standard
technique has not yet been identified and, as shown in Ta-
ble 1, different techniques on different samples have been
used in the included studies. In our meta-analysis, we have
tried to address this issue by splitting analyses according to
different techniques used for 8-OHdG measurement (ELISA
or MS). While data were entirely confirmed in studies using
the ELISA method, only a trend not achieving statistical
significance was found in the studies in which MS techniques
were used. However, the lack of a significant association in
this latter group of studies could be partly explained by the
relatively low number of studies (n = 3) using MS for the
dosage of 8-OHdG levels. In addition, differences in 8-OHdG
levels have been consistently confirmed both in studies per-
formed on urine samples and in studies on blood samples.
Although it was not possible to conclusively ascertain sour-
ces of heterogeneity, all results were confirmed after adjust-
ing for the presence of publication bias.
In conclusion, 8-OHdG is significantly associated with
both CAD and other types of atherosclerotic processes
(stroke, peripheral artery disease, and carotid atherosclero-
sis). The standardization of a laboratory technique for 8-
OHdG assessment, however, is still needed to allow for large
prospective studies that are able to test 8-OHdG as a predictor
of CVD.
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